Objective To evaluate the long-term outcomes of patients with advanced N-stage nasopharyngeal carcinoma (NPC) treated by intensity-modulated radiotherapy (IMRT) and the effects of IMRT combined with different chemotherapies on the patients′ prognosis. Methods A retrospective analysis was performed on the clinical data of 179 patients with advanced N-stage NPC who were admitted to our hospital from January 2001 to January 2008. Of the 179 patients, 33 received IMRT alone, and 146 received chemoradiotherapy (CRT). Among the 146 patients, 71 received concurrent chemoradiotherapy (CCRT), 66 received induction chemotherapy (IC) plus CCRT, and 9 received CCRT plus adjuvant chemotherapy (AC). Results The follow-up rate was 96.5%, and 133 patients were followed up for at least 5 years. The 5-year overall survival rate was 69.0%. The patients receiving IMRT alone and patients receiving CRT had 5-year overall survival rates of 47.7% and 73.7%(χ2=13.91, P=0.000), 5-year distant metastasis-free survival (DMFS) rates of 49.2% and 68.3%(χ2=4.97, P=0.026), relapse-free survival rates of 74.5% and 92.4%(χ2=9.87, P=0.002), and progression-free survival rates of 37.5% and 65.1%(χ2=11.65, P=0.001). Among the patients receiving CRT, those receiving CCRT, IC plus CCRT, and CCRT plus AC had similar survival rates. IC plus CCRT resulted in a significantly higher DMFS than IMRT alone (χ2=4.65, P=0.031). Conclusions The distant metastasis rate is still high in patients with advanced N-stage NPC after IMRT, for whom IC plus concurrent chemotherapy and IMRT may be a better treatment regimen.
SUN Xue-ming,HUANG Ying,CHEN Chun-yan et al. Long-term outcomes of patients with advanced N-stage nasopharyngeal carcinoma treated by intensity-modulated radiotherapy alone or with chemotherapy[J]. Chinese Journal of Radiation Oncology, 2013, 22(3): 225-229.
[1] Wong FC, Ng AW, Lee VH, et al. Whole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys,2010,76:138-145. [2] Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma:radiation therapy oncology group phase Ⅱ trial 0225. J Clin Oncol,2009,27:3684-3690. [3] 陈春燕,韩非,赵充,等.934例鼻咽癌单纯放疗远期疗效分析.中华放射肿瘤学杂志,2008,17:411-415. [4] Cheng SH, Yen KL, Jian JJ,et al. Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy:impact on future clinical trials. Int J Radiat Oncol Biol Phys,2001,50:717-726. [5] 易俊林,高黎,徐国镇,等.147例鼻咽癌调强放疗结果分析.中华放射肿瘤学杂志,2008,17:329-334. [6] 赵充,卢泰祥,韩非,等.139例鼻咽癌调强放疗的临床研究.中华放射肿瘤学杂志,2006,15:l-6. [7] Butler EB, The BS, Grant WH, et al.Smart (simultaneous modulated accelerated radiation therapy) boost:a new accelerated fraetionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys,1999,45:21-32. [8] Chau RM, Teo PM, Kam MK, et al. Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma:to treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord. Med Dosim,2007,32:263-270. [9] Al-Sarraf M, LeBlanc M, Giri PG,et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer:phase Ⅲ randomized Intergroup study 0099. J Clin Oncol,1998,16:1310-1317. [10] Lee AW, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma:NPC-9901 trial by the HongKong nasopharyngeal cancer study group. J Clin Oncol,2005,23:6966-6975. [11] Baujat B, Bourhis J, Chan AT, et al.Chemotherapy in locally advanced nasopharyngeal carcinoma:an individual patient datameta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys,2006,64:47-56. [12] Lin S, Lu JJ, Han L, et al. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma:experience of 370 consecutive cases. BMC Cancer,2010,10:39. [13] 易俊林,高黎,黄晓东,等.416例鼻咽癌调强放疗远期生存与影响因素分析.中华放射肿瘤学杂志,2012,21:196-200. [14] Chua DT, Sham JS, Au GK, et al. Concomitant chemoirradiation for stage Ⅲ-IV nasopharyngeal carcinoma in Chinese patients:results of a matched cohort analysis. Int J Radiat Oncol Biol Phys,2002,53:334-343. [15] Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma:a pooled data analysis of two phase Ⅲ trials. J Clin Oncol,2005,23:1118-1124. [16] Hui EP, Ma BB, Leung SF, et al. Randomized phase Ⅱ trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol,2009,27:242-249.